Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?

@article{Seyfried2019ProvocativeQS,
  title={Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?},
  author={Thomas N. Seyfried and Laura Marie Shelton and Gabriel J Arismendi-Morillo and Miriam Kalamian and Ahmed Elsakka and Joseph C. Maroon and Purna Mukherjee},
  journal={Neurochemical Research},
  year={2019},
  pages={1-13}
}
No major advances have been made in improving overall survival for glioblastoma (GBM) in almost 100 years. The current standard of care (SOC) for GBM involves immediate surgical resection followed by radiotherapy with concomitant temozolomide chemotherapy. Corticosteroid (dexamethasone) is often prescribed to GBM patients to reduce tumor edema and inflammation. The SOC disrupts the glutamate–glutamine cycle thus increasing availability of glucose and glutamine in the tumor microenvironment… CONTINUE READING
32
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 169 REFERENCES

Immunotherapy for glioblastoma: quo vadis?

  • Nature Reviews Clinical Oncology
  • 2019
VIEW 1 EXCERPT